KYMR vs NBIX: stock comparison and AI forecast
Kymera Therapeutics, Inc. (KYMR) and Neurocrine Biosciences Inc (NBIX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
KYMR Kymera Therapeutics, Inc.
- Market Cap
- $10.94B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
NBIX Neurocrine Biosciences Inc
- Price
- $159.76 +6.8% · 6M
- Market Cap
- $16.24B
- P/E Ratio
- 23.4x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- NBIX is 1.5 times larger than KYMR by market capitalization ($16.24B against $10.94B).
- NBIX turns 19.0% of its revenue into net income, against -514.8% for KYMR.
- NBIX carries 0.45 times debt per unit of equity, against 0.09 times for KYMR.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | KYMR | NBIX |
|---|---|---|
| Market Cap | $10.94B | $16.24B |
| P/E Ratio | – | 23.39x |
| P/B Ratio | 6.77x | 4.19x |
| EPS | $-3.74 | $6.83 |
| Book Value/Share | $18.91 | $38.16 |
| Revenue/Share | $0.80 | $36.42 |
| FCF/Share | $-3.38 | $10.23 |
Profitability & Margins
| Metric | KYMR | NBIX |
|---|---|---|
| ROE | -21.6% | 18.1% |
| ROA | -19.8% | 12.5% |
| ROIC | -24.1% | 19.1% |
| Gross Margin | 0.0% | 98.2% |
| Operating Margin | -596.6% | 24.0% |
| Net Margin | -514.8% | 19.0% |
| EBT Margin | -540.5% | 25.2% |
| Tax Rate | – | 24.6% |
Financial Health
| Metric | KYMR | NBIX |
|---|---|---|
| Current Ratio | 11.13x | 2.04x |
| Quick Ratio | – | 1.97x |
| D/E Ratio | 0.09x | 0.45x |
| Financial Leverage | 1.09x | 1.45x |
| Interest Coverage | -3200.7x | 122.7x |
| Working Capital | $909M | $1.02B |
Cash Flow
| Metric | KYMR | NBIX |
|---|---|---|
| Operating Cash Flow | -$288M | $1.07B |
| Free Cash Flow | -$289M | $1.04B |
| Capital Spending | -$1M | -$26M |
| OCF Growth YoY | – | 67.4% |
| FCF Growth YoY | – | 75.3% |
| FCF/Sales | -425.6% | 28.1% |
| CapEx/Sales | 2.0% | 0.7% |
Operational Efficiency
| Metric | KYMR | NBIX |
|---|---|---|
| Asset Turnover | 0.04x | 0.66x |
| Receivables Turnover | – | 3.9x |
| Inventory Turnover | – | 1.0x |
| Fixed Assets Turnover | 1.8x | 40.1x |
| Days Sales Outstanding | – | 94 days |
| Days Inventory | – | 358 days |
| Payables Period | 64 days | 815 days |
| Cash Conversion Cycle | – | -363 days |
Income Statement
| Metric | KYMR | NBIX |
|---|---|---|
| Total Revenue | $68M | $3.70B |
| Operating Income | -$405M | $887M |
| Net Income | -$349M | $702M |
| R&D Expense | $430M | $1.23B |
| SG&A Expense | – | $1.43B |
| Cost of Goods Sold | $68M | $67M |
Dividend & Shareholder Information
| Metric | KYMR | NBIX |
|---|---|---|
| Shares Outstanding | 85M | 102M |
| Net Income Growth | – | 64.1% |
| EPS Growth | – | 51.1% |
KYMR vs NBIX: stock comparison and AI forecast
Which is bigger, KYMR or NBIX?
NBIX is 1.5 times larger than KYMR by market capitalization ($16.24B against $10.94B).
Which one does Intratio's AI model rank higher, KYMR or NBIX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.